Last reviewed · How we verify
XZP-3287;Letrozole;Anastrozole;Fulvestrant
XZP-3287;Letrozole;Anastrozole;Fulvestrant is a Small molecule drug developed by Sihuan Pharmaceutical Holdings Group Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | XZP-3287;Letrozole;Anastrozole;Fulvestrant |
|---|---|
| Sponsor | Sihuan Pharmaceutical Holdings Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XZP-3287;Letrozole;Anastrozole;Fulvestrant CI brief — competitive landscape report
- XZP-3287;Letrozole;Anastrozole;Fulvestrant updates RSS · CI watch RSS
- Sihuan Pharmaceutical Holdings Group Ltd. portfolio CI
Frequently asked questions about XZP-3287;Letrozole;Anastrozole;Fulvestrant
What is XZP-3287;Letrozole;Anastrozole;Fulvestrant?
XZP-3287;Letrozole;Anastrozole;Fulvestrant is a Small molecule drug developed by Sihuan Pharmaceutical Holdings Group Ltd..
Who makes XZP-3287;Letrozole;Anastrozole;Fulvestrant?
XZP-3287;Letrozole;Anastrozole;Fulvestrant is developed by Sihuan Pharmaceutical Holdings Group Ltd. (see full Sihuan Pharmaceutical Holdings Group Ltd. pipeline at /company/sihuan-pharmaceutical-holdings-group-ltd).
What development phase is XZP-3287;Letrozole;Anastrozole;Fulvestrant in?
XZP-3287;Letrozole;Anastrozole;Fulvestrant is in Phase 1.